Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
rhIGF-1 (CEP-151) in Multiple Sclerosis
NCT00001669Phase 2Completed
- Sponsor
- National Institute of Neurological Disorders and Stroke
- Start
- Jul 1997
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 1
01
Overview
A Phase 2 trial of mecasermin in multiple sclerosis (MS), sponsored by National Institute of Neurological Disorders and Stroke. Started Jul 1997; status: completed.
02
Drugs
mecasermin
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT00001669.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00001669.